SLC5A2 and diabetic kidney disease: Angiotensin-converting enzyme inhibitors, ARBs, SGLT2 inhibitors, and the nonsteroidal mineralocorticoid receptor antagonist finerenone have all been shown to improve renal and cardiac function in patients with DKD in kidney disease outcome trials.